These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28432573)

  • 41. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
    Teramoto T; Uno K; Miyoshi I; Khan I; Gorcyca K; Sanchez RJ; Yoshida S; Mawatari K; Masaki T; Arai H; Yamashita S
    Atherosclerosis; 2016 Aug; 251():248-254. PubMed ID: 27419905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.
    Kreisberg RA; Oberman A
    J Clin Endocrinol Metab; 2002 Feb; 87(2):423-37. PubMed ID: 11836262
    [No Abstract]   [Full Text] [Related]  

  • 44. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. "Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con).
    Sakamoto T; Ogawa H
    Circ J; 2010 Aug; 74(8):1731-41. PubMed ID: 20671372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-density lipoprotein cholesterol: how low can we go?
    Sherbet DP; Garg P; Brilakis ES; Banerjee S
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population.
    Rodriguez F; Olufade TO; Ramey DR; Friedman HS; Navaratnam P; Heithoff K; Foody JM
    J Womens Health (Larchmt); 2016 Jul; 25(7):697-706. PubMed ID: 26889924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.
    Alsayed N; Almahmeed W; Alnouri F; Al-Waili K; Sabbour H; Sulaiman K; Zubaid M; Ray KK; Al-Rasadi K
    Atherosclerosis; 2022 Feb; 343():28-50. PubMed ID: 35091265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New lipid-modifying therapies.
    Bruckert E
    Expert Opin Investig Drugs; 2003 Mar; 12(3):325-35. PubMed ID: 12605558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibrates after the FIELD study: Some answers, more questions.
    Wierzbicki AS
    Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New advances in lipid-modifying therapies for reducing cardiovascular risk.
    Bruckert E
    Cardiology; 2002; 97(2):59-66. PubMed ID: 11978950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipid Lowering Therapy to Modify Plaque Microstructures.
    Kataoka Y; Andrews J; Puri R; Psaltis P; Nicholls SJ
    J Atheroscler Thromb; 2017 Apr; 24(4):360-372. PubMed ID: 28239070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.